DocGo (NASDAQ:DCGO) vs. IceCure Medical (NASDAQ:ICCM) Financial Analysis

DocGo (NASDAQ:DCGO) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation & Earnings

This table compares DocGo and IceCure Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20 million	0.18	-$182.40 million	($1.91)	-0.30
IceCure Medical	$3.38 million	126.77	-$15.06 million	($0.24)	-21.20

IceCure Medical has lower revenue, but higher earnings than DocGo. IceCure Medical is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of DocGo shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 3.8% of DocGo shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for DocGo and IceCure Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1	2	3	0	2.33
IceCure Medical	1	1	3	0	2.40

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 313.76%. IceCure Medical has a consensus target price of $62.70, indicating a potential upside of 1,132.07%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than DocGo.

Volatility and Risk

DocGo has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, IceCure Medical has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares DocGo and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
IceCure Medical	-441.60%	-211.73%	-119.13%

Summary

DocGo beats IceCure Medical on 8 of the 13 factors compared between the two stocks.

About DocGo

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.